A detailed history of Geode Capital Management, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,480,187 shares of BPMC stock, worth $134 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,480,187
Previous 1,459,484 1.42%
Holding current value
$134 Million
Previous $157 Million 13.0%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$84.1 - $120.5 $1.74 Million - $2.49 Million
20,703 Added 1.42%
1,480,187 $137 Million
Q2 2024

Aug 09, 2024

BUY
$85.18 - $108.78 $7.53 Million - $9.61 Million
88,357 Added 6.44%
1,459,484 $157 Million
Q1 2024

May 13, 2024

BUY
$73.17 - $99.79 $3.21 Million - $4.38 Million
43,871 Added 3.31%
1,371,127 $130 Million
Q4 2023

Feb 13, 2024

BUY
$43.96 - $92.84 $2.67 Million - $5.64 Million
60,759 Added 4.8%
1,327,256 $122 Million
Q3 2023

Nov 13, 2023

BUY
$46.9 - $66.0 $2.12 Million - $2.99 Million
45,304 Added 3.71%
1,266,497 $63.6 Million
Q2 2023

Aug 11, 2023

BUY
$42.2 - $66.37 $2.47 Million - $3.89 Million
58,553 Added 5.04%
1,221,193 $77.2 Million
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $1.83 Million - $2.42 Million
48,303 Added 4.33%
1,162,640 $52.3 Million
Q4 2022

Feb 13, 2023

BUY
$41.06 - $66.48 $1.6 Million - $2.6 Million
39,044 Added 3.63%
1,114,337 $48.8 Million
Q3 2022

Nov 14, 2022

BUY
$49.93 - $77.7 $1.32 Million - $2.05 Million
26,344 Added 2.51%
1,075,293 $70.9 Million
Q2 2022

Aug 12, 2022

BUY
$45.23 - $70.15 $558,183 - $865,721
12,341 Added 1.19%
1,048,949 $53 Million
Q1 2022

May 13, 2022

BUY
$54.1 - $110.08 $361,225 - $735,004
6,677 Added 0.65%
1,036,608 $66.2 Million
Q4 2021

Feb 11, 2022

BUY
$94.25 - $115.99 $1.59 Million - $1.96 Million
16,881 Added 1.67%
1,029,931 $110 Million
Q3 2021

Nov 12, 2021

SELL
$80.98 - $109.47 $741,047 - $1 Million
-9,151 Reduced 0.9%
1,013,050 $104 Million
Q2 2021

Aug 13, 2021

BUY
$82.78 - $101.0 $4.61 Million - $5.63 Million
55,705 Added 5.76%
1,022,201 $89.9 Million
Q1 2021

May 12, 2021

BUY
$90.71 - $108.28 $9.12 Million - $10.9 Million
100,534 Added 11.61%
966,496 $94 Million
Q4 2020

Feb 12, 2021

BUY
$92.08 - $124.48 $4.17 Million - $5.63 Million
45,264 Added 5.52%
865,962 $97.1 Million
Q3 2020

Nov 13, 2020

SELL
$66.45 - $92.7 $173,168 - $241,576
-2,606 Reduced 0.32%
820,698 $76.1 Million
Q2 2020

Aug 13, 2020

BUY
$57.09 - $79.27 $1.7 Million - $2.35 Million
29,695 Added 3.74%
823,304 $64.2 Million
Q1 2020

May 14, 2020

BUY
$48.11 - $82.22 $4.92 Million - $8.41 Million
102,291 Added 14.8%
793,609 $46.4 Million
Q4 2019

Feb 13, 2020

BUY
$66.73 - $82.59 $1.98 Million - $2.45 Million
29,612 Added 4.48%
691,318 $55.4 Million
Q3 2019

Nov 12, 2019

BUY
$72.9 - $101.41 $610,829 - $849,714
8,379 Added 1.28%
661,706 $48.6 Million
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $8.56 Million - $11.4 Million
116,404 Added 21.68%
653,327 $61.6 Million
Q1 2019

May 14, 2019

BUY
$48.7 - $86.6 $2.16 Million - $3.83 Million
44,261 Added 8.98%
536,923 $43 Million
Q4 2018

Feb 13, 2019

BUY
$45.57 - $74.26 $1.39 Million - $2.26 Million
30,499 Added 6.6%
492,662 $26.6 Million
Q3 2018

Nov 13, 2018

BUY
$58.91 - $78.32 $3.2 Million - $4.26 Million
54,352 Added 13.33%
462,163 $36.1 Million
Q2 2018

Aug 14, 2018

BUY
$60.96 - $101.18 $1.92 Million - $3.18 Million
31,415 Added 8.35%
407,811 $25.9 Million
Q1 2018

May 15, 2018

BUY
$73.28 - $102.95 $513,326 - $721,164
7,005 Added 1.9%
376,396 $34.5 Million
Q4 2017

Feb 13, 2018

BUY
$62.91 - $88.32 $2.23 Million - $3.13 Million
35,455 Added 10.62%
369,391 $27.9 Million
Q3 2017

Nov 14, 2017

BUY
$42.37 - $69.67 $756,050 - $1.24 Million
17,844 Added 5.65%
333,936 $23.3 Million
Q2 2017

Aug 14, 2017

BUY
N/A
316,092
316,092 $16 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.